Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | PDE5A | O76074 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8585279 | 0.84 | NR1H4 (0.47) | NR1H4MAOBPDE5ALTB4R | |
| SCHEMBL8581492 | 0.82 | HTR1A (0.51) | NR1H4MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6807773 | 0.81 | NR1H4 (0.47) | NR1H4MAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL26158672 | 0.81 | MAOB (0.55) | NR1H4MAOBMAPTCYP2C9CYP2C19 | |
| SCHEMBL6899767 | 0.80 | NR1H4 (0.46) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL8582404 | 0.80 | NR1H4 (0.46) | NR1H4MAOBMAPTSMN1; SMN2TDP1 | |
| SCHEMBL2942741 | 0.79 | MAOB (0.52) | NR1H4MAOBPDE5AMAPTCYP2C9 | |
| SCHEMBL16482745 | 0.78 | CYP3A4 (0.56) | NR1H4MAPTL3MBTL1LTB4RLTB4R2 | |
| SCHEMBL9046839 | 0.78 | ALOX5 (0.46) | MAOBMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL384030 | 0.78 | MAOB (0.57) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | SAWYER JASON SCOTT (US) | 2004-10-07 | — | — | US | disclosed |
| US-6797723-B1 | Heterocycle substituted diphenyl leukotriene antagonists | ELI LILLY AND COMPANY | 2004-09-28 | — | — | US | disclosed |
| EP-1263743-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001034197-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034580-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | LTB4R, LTB4R2, LTA4H | NR1H4 233/4885MAOB 667/4885PDE5A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.